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Background
We recently identified RIG-I-like helicases (RLH) as
therapeutic targets of pancreatic cancer for counteract-
ing immunosuppressive mechanisms and apoptosis
induction. Here, we investigated immunogenic conse-
quences of RLH-induced tumour cell death.
Material and methods
Murine pancreatic cancer cells (Panc02) were treated with
RLH ligands to induce apoptosis and were then cocultured
with primary dendritic cells (DC). DC maturation marker
expression, antigen uptake and antigen cross-presentation
were assessed.
Results
RLH ligands induced production of type I IFN, HMGB1
and Hsp70 and translocation of calreticulin to the outer
cell membrane of tumour cells. In cocultures, DC upregu-
lated B7 expression, which was mediated by tumour-
derived type I IFN, whereas TLR, RAGE or inflammasome
signaling was dispensable. CD8a+ DC effectively engulfed
apoptotic tumour material and cross-presented tumour-
associated antigen to naïve CD8+ T cells. In comparison,
tumour cell death mediated by oxaliplatin, staurosporine
or mechanical disruption failed to induce DC activation,
antigen uptake or cross-presentation. Moreover, tumour
cells treated with sublethal doses of RLH ligands upregu-
lated MHC-I and Fas expression and were sensitised
towards CTL- and Fas-mediated killing.
Conclusions
RLH ligands induce a highly immunogenic form of
tumour cell death linking innate and adaptive immunity.
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